{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:14:37Z","timestamp":1792656877250,"version":"4.5.0"},"reference-count":13,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,11,30]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Pemphigus vulgaris is an autoimmune bullous disease that involves the skin and mucous membranes. Current therapies aim to decrease antibody production by means of the use of systemic corticosteroids, immunosuppressive agents and, recently, rituximab, an anti-CD20 monoclonal antibody. However, the chronic immune suppression could entail complications, like infections and secondary malignancies. We describe a case of a patient with pemphigus who developed a sepsis due to <jats:italic>Citrobacter freundii<\/jats:italic> infection.<\/jats:p>","DOI":"10.1136\/bcr-2018-227091","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e227091","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["<i>Citrobacter freundii<\/i> sepsis in an immunosuppressed patient with pemphigus vulgaris"],"prefix":"10.1136","volume":"11","author":[{"given":"Martina","family":"Ferranti","sequence":"first","affiliation":[{"name":"Unit of Dermatology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tadiotto Cicogna","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sattin","sequence":"additional","affiliation":[{"name":"Unit of Infectious Disease, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"2025082710212777000_11.1.e227091.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025082710212777000_11.1.e227091.2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert","year":"2018","journal-title":"Immunotherapy"},{"key":"2025082710212777000_11.1.e227091.3","doi-asserted-by":"publisher","DOI":"10.1186\/ar3908"},{"key":"2025082710212777000_11.1.e227091.4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"2025082710212777000_11.1.e227091.5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmii.2016.08.016","article-title":"Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes","volume":"51","author":"Liu","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"2025082710212777000_11.1.e227091.6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jiac.2016.07.003","article-title":"Bacteremia due to Citrobacter braakii: A case report and literature review","volume":"22","author":"Hirai","year":"2016","journal-title":"J Infect Chemother"},{"key":"2025082710212777000_11.1.e227091.7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2340\/00015555-0762","article-title":"Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia","volume":"90","author":"Kluger","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"2025082710212777000_11.1.e227091.8","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47441-0"},{"key":"2025082710212777000_11.1.e227091.9","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.1.115"},{"key":"2025082710212777000_11.1.e227091.10","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/bjd.15947","article-title":"Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus","volume":"177","author":"Murrell","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082710212777000_11.1.e227091.11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.18176\/jiaci.0283","article-title":"Persistent B Lymphocyte Depletion After an Ultralow Dose of Rituximab for Pemphigus Vulgaris","volume":"28","author":"Lazzarotto","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025082710212777000_11.1.e227091.12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3389\/fimmu.2018.00810","article-title":"Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions","volume":"9","author":"Alaibac","year":"2018","journal-title":"Front Immunol"},{"key":"2025082710212777000_11.1.e227091.13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-227091","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:21:35Z","timestamp":1756315295000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,17]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-227091"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227091","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}